Results 21 to 30 of about 16,213 (203)

Successful treatment of invasive tracheobronchial pulmonary aspergillosis with venovenous extracorporeal membrane oxygenation and combined systemic, intratracheal instillation of liposomal amphotericin B: a case report

Journal of Medical Case Reports, 2022
Background Invasive pulmonary Aspergillus and invasive bronchial aspergillosis is a life-threatening opportunistic fungal infection that predominantly affects immunocompromised hosts.
Shuku Sato, Wataru Kamata, Kiyomitsu Fukaguchi, Shun Tsunoda, Tadashi Kamio, Hiroshi Koyama, Hideyasu Sugimoto, Yotaro Tamai   +7 more
doaj   +1 more source

Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report

Frontiers in Pediatrics, 2023
BackgroundNephrotoxicity is the most frequent serious adverse effect associated with amphotericin B deoxycholate treatment, for this reason, in recent years it has been relegated from routine clinical practice and replaced by the new liposomal ...
Adrian Puertas Sanjuan, Carlos Javier Parramón-Teixidó, Susana Hernandez-Perez, Marie Antoinette Frick, Maria Jose Cabañas Poy   +4 more
doaj   +1 more source

AMBITION-cm : intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa : study protocol for a randomized controlled trial [PDF]

, 2015
Cryptococcal meningitis (CM) is a leading cause of mortality among HIV-infected individuals in Africa. Poor outcomes from conventional antifungal therapies, unavailability of flucytosine, and difficulties administering 14 days of amphotericin B are key ...
Leeme, Tshepo, Síle F. Molloy, Changalucha, John M., Molefi, Mooketsi, Molloy, Síle F, Meintjes, Graeme, Molloy, Síle F., Goldberg, Drew W, John R. Perfect, Drew W. Goldberg, Kalluvya, Samuel, Cainelli, Francesca, Letang, Emili, Ndhlovu, Chiratidzo E, Perfect, John R, Ndhlovu, Chiratidzo E., Bisson, Gregory P., Miriam Haverkamp, Burton, Rosie, Rosie Burton, Tariro Makadzange, Harrison, Thomas S, Francesca Cainelli, Hope, William, Haverkamp, Miriam, Chiratidzo E. Ndhlovu, Harrison, Thomas S., Jarvis, Joseph N., Chofle, Awilly A, William Hope, Jarvis, Joseph N, Changalucha, John M, Fenner, Lukas, Perfect, John R., Makadzange, Tariro, Joseph N. Jarvis, Tshepo Leeme, Mooketsi Molefi, Nametso Lekwape, Lekwape, Nametso, John M. Changalucha, Emili Letang, Goldberg, Drew W., Lukas Fenner, Bisson, Gregory P, Awilly A. Chofle, Samuel Kalluvya, Thomas S. Harrison, Graeme Meintjes, Chofle, Awilly A., Gregory P. Bisson   +50 more
core   +1 more source

Safety and usefulness of nebulized liposomal amphotericin B: Systematic scoping review [PDF]

, 2023
Purpose Invasive fungal infections potentially result in fatal outcomes in immunocompromised hosts. Compared to intravenous administration, a nebulization therapy can achieve a high concentration of drug delivered in the respiratory tract, without a ...
Hagiya, Hideharu, Otsuka, Fumio, Nishimura, Yoshito   +2 more
core   +2 more sources

Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a New In Vitro Pharmacokinetic/Pharmacodynamic Model [PDF]

, 2011
In conventional MIC tests, fungi are exposed to constant drug concentrations, whereas in vivo, fungi are exposed to changing drug concentrations.
Thomas J. Walsh, Emmanuel Roilides, Aristea Velegraki, Walsh, Thomas, Zerva, Loukia, Meletiadis, Joseph, Joseph Meletiadis, Roilides, Emmanuel, Rafal Al-Saigh, Velegraki, Aristea, Loukia Zerva, Al Saigh, Rafal   +11 more
core   +1 more source

Potency and stability of liposomal Amphotericin B formulated for topical management of Aspergillus spp. infections in burn patients

Burns Open, 2020
Background: Systemic fungal infections are an important mortality factor when considering severely burned patients. Preventive topical pharmacotherapeutic management of deep fungal infections remains of secondary concern when initially treating a burn ...
Alexis Laurent, Olivier Pantet, Lydie Laurent, Nathalie Hirt-Burri, Anthony de Buys Roessingh, Wassim Raffoul, Philippe Laurent, Michel Monod, Lee Ann Applegate   +8 more
doaj   +1 more source

Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil

Revista da Sociedade Brasileira de Medicina Tropical, 2019
INTRODUCTION: Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.
Tália Santana Machado de Assis, Ana Rabello, Gláucia Cota, Guilherme Loureiro Werneck, André Luís Ferreira de Azeredo-da-Silva   +4 more
doaj   +1 more source

HIV-associated disseminated histoplasmosis successfully treated with isavuconazole consolidation therapy

Medical Mycology Case Reports, 2020
A 30-year-old man with advanced HIV and disseminated histoplasmosis deteriorated after stepping down from intravenous liposomal amphotericin B to itraconazole.Therapeutic levels of itraconazole and posaconazole were not achieved, therefore liposomal ...
Andrea Mazzella, Neil R.H. Stone, Erica R.M. Pool, Ana García Mingo, Sorina Bolache, Chris Wood   +5 more
doaj   +1 more source

Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report

Revista da Sociedade Brasileira de Medicina Tropical, 2019
In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate.
Benivaldo Ramos Ferreira Terceiro, Tania Salgado de Souza Torraca, Frederico Pereira Bom Braga, Ana Cristina da Costa Martins, Lucia Regina Brahim, Mauricio Naoto Saheki, Luciana de Freitas Campos Miranda, Armando de Oliveira Schubach, Cláudia Maria Valete-Rosalino   +8 more
doaj   +1 more source

Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine

Medical Mycology Case Reports, 2014
A patient with Candida spondylitis failed two weeks of fluconazole combined with caspofungin, and the infection relapsed despite six weeks of liposomal amphotericin B followed by two months of fluconazole.
Line Storm, Karen R. Lausch, Maiken C. Arendrup, Klaus L. Mortensen, Eskild Petersen   +4 more
doaj   +1 more source